Retatrutide is an investigational triple-receptor agonist. Phase 3 evidence is available, while regulatory approval remains a separate milestone.
TRIUMPH-1 evaluated adults with obesity without diabetes over 80 weeks. The published treatment-regimen estimate differs in purpose from hypothetical continued-treatment estimates. Read the paper’s population, analysis, and adverse-event reporting beside any weight-loss percentage.
The trial registry identifies the study design and sponsor. It does not verify clinical-trial eligibility for a reader or authenticate products sold outside the research setting.
There is no approved dose or brand verified here. An online product using the molecule’s name should not be assumed equivalent to the clinical-trial material.
Regulatory status checked on 3 October 2026
United States: FDA states retatrutide is not a component of an FDA-approved drug; current sponsor sources call it investigational. Trial publication does not establish routine marketing approval.
European Union: EU marketing authorisation has not been verified in this review. A research or pediatric-development document is not sufficient evidence of authorisation.
Official records and primary evidence
- FDA GLP-1 safety communication — FDA
- Retatrutide development update — Eli Lilly
- TRIUMPH-1 Phase 3 paper — TRIUMPH-1 investigators / NEJM
- TRIUMPH-1 trial registry — ClinicalTrials.gov / Eli Lilly
Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.